Effect of LSD on Lipid Profiles Within 1 Year Postoperatively in Cirrhosis Patients With Portal Hypertension Bleeding

NCT07811700 | Completed

• 1 other identifier: YZUC-024
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with liver cirrhosis frequently exhibit dyslipidemia due to impaired hepatic lipid synthesis, altered bile acid metabolism, and portal hypertension. Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) is commonly used to treat Cirrhosis with Portal Hypertension Bleeding in these patients, but its impact on lipid profiles within 1 year postoperatively remains poorly characterized. This study will follow patients undergoing LSD to measure changes in serum lipid parameters before and after surgery, identify risk factors for lipid profile deterioration or improvement, and determine whether LSD can ameliorate dyslipidemia in the long term, thereby informing metabolic management strategies in cirrhotic patients.

Conditions

Lipid Profiles; Cirrhosis, Liver; Portal Hypertension; Splenectomy; Status

Keywords

Cirrhosis; Splenectomy; Laparoscopy; Lipid Profiles; azygoportal disconnection; hypersplenism; Portal Hypertension Bleeding

Outcome Measures

Primary Outcomes (4)

• Total triglycerides (TG) level

  Change in total triglycerides (TG) level

  baseline, postoperative month 3, month 6, month 9, month 12,

• Total cholesterol (TC) leve

  Change in total cholesterol (TC) level

  baseline, and postoperative month 3, month 6, month 9,month 12

• High-density lipoprotein cholesterol (HDL-C)

  Change in high-density lipoprotein cholesterol (HDL-C) level

  baseline, and postoperative month 3, month 6, month 9,month 12,

• Low-density lipoprotein cholesterol (LDL-C)

  Change in low-density lipoprotein cholesterol (LDL-C) level

  baseline, and postoperative month 3, month 6, month 9, month 12,

Secondary Outcomes (2)

• albumin, bilirubin

  baseline, and postoperative month 3, month 6, month 9, month 12,

• Child-Pugh grade

  baseline, and postoperative month 3, month 6, month 9,month 12,

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Retrospective, single-center, observational cohort study. Medical records of patients with cirrhosis, splenomegaly and hypersplenism, and portal hypertension bleeding who had undergone Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) were reviewed. Preoperative baseline data and postoperative data at 3, 6, 9, and 12 months were extracted to evaluate dynamic changes in lipid profiles within 1 year postoperatively.

You may qualify if:

• Age 18-80 years, male or female
• Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
• Splenomegaly and hypersplenism
• History of portal hypertension bleeding (esophageal and gastric variceal bleeding )
• Child-Pugh Class A or B liver function
• Ability to complete 12-month follow-up

You may not qualify if:

• Child-Pugh Class C liver cirrhosis
• Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection
• Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
• Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery.
• Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases.
• Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery
• Pregnancy or lactation
• Poor compliance, inability to complete follow-up

Sponsors & Collaborators

• Northern Jiangsu People's Hospital: lead

Study Sites (1)

Clinical Medical College of Yangzhou University

Yangzhou, Jiangsu, 225001, China

Location

MeSH Terms

Conditions

Liver Cirrhosis; Hypertension, Portal; Fibrosis; Hypersplenism

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Splenic Diseases; Lymphatic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Guo-Qing Jiang, MD

  Clinical Medical College of Yangzhou University

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: September 3, 2026
• First Posted: September 10, 2026
• Study Start: May 1, 2022
• Primary Completion: May 1, 2025
• Study Completion: July 15, 2026
• Last Updated: September 10, 2026

Record last verified: 2026-09

Locations

CN (1)